Rheumatology
| Rheumatoid Arthritis
Rheumatology
Rheumatoid Arthritis

Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis

book_2 Source: ACR Convergence 2020 - Poster session - Abs #0237
calendar_today Published on Medfyle: November 2020
headphones 2 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • Data from five randomized phase  3 trials in the upadacitinib SELECT rheumatoid arthritis program were analyzed.
  • The safety profile over 2309.7 patient–years of exposure was comparable to previous analyses, with no new safety risks identified.
  • The most frequent treatment-emergent adverse events with upadacitinib were upper respiratory tract infection, nasopharyngitis, and urinary tract infection.
  • Follow-up of upadacitinib patients continues in long-term extensions and post-marketing safety studies.
Presenting Author
Read more arrow_downward Hide arrow_upward

Stanley Cohen, MD
Metroplex Clinical Research Center
MD

Dr. Cohen is a Clinical Professor in the Department of Internal Medicine at UT Southwestern Medical Center and Co-Director of the Division of Rheumatology at Presbyterian Hospital, Dallas. He also is Co-Medical Director of Metroplex Clinical Research Center. He is a past president of the American College of Rheumatology and was honored in 2016 with the designation of Master by the American College of Rheumatology. Dr. Cohen completed a degree in biology from the University of Virginia and received his Doctor of Medicine with honors, from the University of Alabama School of Medicine in Birmingham. He completed an internship and residency in Internal Medicine at Parkland Memorial Hospital, Dallas, Texas, and a fellowship in Rheumatology at UT Southwestern/St. Paul University Hospital. For the last 30 years Dr. Cohen has been involved in clinical trials in rheumatoid arthritis as a principal investigator and have played pivotal roles in protocol development and data analysis and have been an author on multiple peer reviewed articles in this field. The majority of the trials have been pharmaceutical funded trials evaluating new molecules for possible registration. Our research group has participated in the development of nearly all the biologic therapies developed for RA in the last 20 years

Presenter disclosures
Read more arrow_downward Hide arrow_upward

S. Cohen, Amgen Inc, AbbVie, Pfizer, Boehringer Ingelheim, Sandoz, Gilead, Eli Lilly


Feedback